# MYOSIN THERAPEUTICS INC.: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | MYOSIN THERAPEUTICS INC. |
| Location | JUPITER, FL |
| Project | Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas |
| Project number | 5R44CA278293-05 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $2,241,448 |
| Awarded | 2026-09-17 |
| Project period | 2023-04-01 to 2027-07-31 |
| UEI | MLH1HUK133H3 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11387631). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.